BioNTech SE has grown revenue −45% a year over three years and 43% a year over five. Revenue growth, 3-year annual rate: −45% (Biotechnology median +17%). Revenue growth, 5-year rate: +43%, growth has slowed since the five-year average. Years of annual history on file: 9, FY2017 to FY2025, as filed.

BNTXBioNTech SE

Healthcare

$96.95+0.76% 1Y

$96.95

$83.8952 weeks$119.34

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−129.5 points).

1 to watch, 1 neutral, 1 without data

Revenue trend+4% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +43% a year.

Margin direction−129.5 points operating

Trailing-twelve-month operating margin, -49.0% now against 80.5% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is BNTX growing?

BioNTech SE has grown revenue −45% a year over three years and 43% a year over five.

−45%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from fiscal years as filed

Revenue growth, 5-year rate: +43%
Revenue growth, 5-year rate · −45% over three · growth has slowed since the five-year average
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed

Details›